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Abstract
Background: We estimated the cost-per-episode and the annual economic burden associated with influenza in
Kenya.
Methods: From July 2013–August 2014, we recruited patients with severe acute respiratory illness (SARI) or
influenza-like illness (ILI) associated with laboratory-confirmed influenza from 5 health facilities. A structured
questionnaire was used to collect direct costs (medications, laboratory investigations, hospital bed fees, hospital
management costs, transportation) and indirect costs (productivity losses) associated with an episode of influenza. We
used published incidence of laboratory-confirmed influenza associated with SARI and ILI, and the national population
census data from 2014, to estimate the annual national number of influenza-associated hospitalizations and outpatient
visits and calculated the annual economic burden by multiplying cases by the mean cost.
Results: We enrolled 275 patients (105 inpatients and 170 outpatients). The mean cost-per-episode of influenza was
US$117.86 (standard deviation [SD], 88.04) among inpatients; US$114.25 (SD, 90.03) for children < 5 years, and US$137.
45 (SD, 76.24) for persons aged ≥5 years. Among outpatients, the mean cost-per-episode of influenza was US$19.82
(SD, 27.29); US$21.49 (SD, 31.42) for children < 5 years, and US$16.79 (SD, 17.30) for persons aged ≥5 years. National
annual influenza-associated cost estimates ranged from US$2.96–5.37 million for inpatients and US$5.96–26.35 million
for outpatients.
Conclusions: Our findings highlight influenza as causing substantial economic burden in Kenya. Further studies may
be warranted to assess the potential benefit of targeted influenza vaccination strategies.,
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Background
In Kenya, influenza virus circulates year-round and is an
important contributor to the acute respiratory illness
associated burden, disproportionately affecting children
aged < 5 years [1, 2]. Despite the documented burden of
influenza disease in Kenya, a national influenza vaccin-
ation program is yet to be implemented. Other than the
health impact caused by influenza virus infection itself,
influenza illness has been shown to exert a considerable
economic burden, although most of the data available
come from temperate and resource rich countries [3–6].
Understanding the costs of influenza-associated illness
in Kenya is critical to allow health authorities and
policy makers to develop practical plans for vaccine
recommendations.
We estimated the cost-per-episode, from a societal
perspective, of laboratory-confirmed influenza-associated
illness in Kenya using data collected from interviews with
case-patients or their care-takers, and abstracted from
medical records. Additionally, we estimated the annual
economic burden of influenza-associated illness in Kenya
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by applying the estimated costs to the annual national
morbidity burden using previously published data on bur-
den of influenza-associated disease.
Methods
Study sites and population
From July 2013 through August 2014, we prospectively
enrolled patients from four hospitals [Mombasa County
Referral Hospital (CRH), Nakuru CRH, Nyeri CRH, and
St. Elizabeth Mission Hospital in Lwak] and one out-
patient facility (Tabitha clinic in Kibera) (Fig. 1). Mombasa
CRH, Nakuru CRH and Nyeri CRH are public health facil-
ities. Kibera clinic is located in an urban informal settle-
ment in Nairobi and is operated by Carolina for Kibera
[7]. St. Elizabeth Mission hospital is a rural site in western
Kenya operated by the Franciscan Sisters of St. Anna [7].
The study sites were purposely selected for their diversity
and their representation of populations in multiple geo-
graphical locations (Fig. 1).
Patients were enrolled if they met the case definitions
for severe acute respiratory illness (SARI) or influenza-like
illness (ILI) and tested positive for influenza A and/or B
using the Becton Dickson (BD) Veritor™ rapid diagnostic
test (RDT) in nasal swabs collected at interview [8, 9].
SARI was defined as hospitalization with an acute re-
spiratory infection within the last ten days with a his-
tory of fever or measured temperature ≥ 38 C°, and
cough. ILI was defined as an acute respiratory infection
Fig. 1 Map of Kenya showing the location of the study sites. Figure is of the authors’ own creation
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within the last seven days with a measured temperature ≥
38 C° and cough.
Confirmatory testing for influenza
Nasopharyngeal (NP) and oropharyngeal (OP) swabs
were collected from all consenting and enrolled patients.
The NP/OP swabs were combined into a single viral
transport media, and tested by real-time reverse tran-
scription polymerase chain reaction (rtRT-PCR) for
influenza A and B virus at the Kenya Medical Research
Institute (KEMRI) and U. S Centers for Disease Control
and Prevention (CDC) laboratory in Nairobi [10]. Data
from patients whose NP/OP specimens were confirmed
to be positive for influenza virus by rtRT-PCR were used
in the final data analysis.
Data collection
Patients who were aged ≥18 years were interviewed dir-
ectly by trained surveillance officers using a structured
questionnaire. For those who were aged < 18 year, their
care-takers were interviewed. Enrolled study participants
were subsequently followed-up using telephone inter-
views to determine additional costs incurred over a
period of 14 days from the date of testing for influenza.
This period was chosen because most uncomplicated
influenza infections resolve within a period of two weeks
[11]. To minimize the possibility of recall bias, the
follow-up telephone interviews were conducted on a
weekly basis. The first interview was conducted on the
8th day (to cover the preceding 7 days); and the last on
the 15th day (to cover the other 7 days). Data on clinical
management of the patients were abstracted from the
medical records of the case-patients (i.e., patient files
and charge sheets). As study participants at the two
population-based study sites receive free medical care
provided by KEMRI and CDC, we used costs chargeable
to non-study participants and costs of purchase provided
by the study administrative staff at Lwak and Kibera,
respectively.
Direct and indirect cost components
The direct cost components included facility-based
medical-cost items (i.e. medications, laboratory investi-
gations and other routine diagnostics, hospital bed fees,
and hospital management costs) (Additional file 2), and
travel costs by the case-patients and/or their household
members. Facility-based medical-cost items were
obtained from the hospital bill charge sheets for inpa-
tients, price catalogue charts, and receipts issued to the
outpatients (Additional file 2 and Additional file 1).
Other direct costs included costs incurred for seeking
care prior and after discharge from the hospital or out-
patient visit (e.g. over the counter prescriptions). Other
than children < 5 years whose medical costs were paid
for by the government in public health facilities, all costs
(excluding consultation fees) were paid for out-of-pocket
by older patients [12]. The costs of testing for influenza
were not included as they are not routinely ordered by
clinicians independently from the ongoing surveillance.
The indirect cost component was the productivity
losses (days of work lost) at the household level by the
case-patients themselves, and/or any of their household
members (Additional file 1). Data on days of work lost
were only considered for those who were engaged in for-
mal or informal income generating employment who
would otherwise not be financially compensated for the
lost workdays.
Data analyses
Descriptive analyses and tests of associations
Data on patient characteristics were described using pro-
portions. Tests of association were performed using
chi-square tests for categorical variables. For continuous
variables, data were described using means, standard
deviations (SD), medians, and interquartile ranges (IQR).
Comparisons of means were done using the independent
t-test or one-way analysis of variance, while medians
were compared using Wilcoxon rank sum test or
Kruskal-Wallis test as appropriate. Data analyses were
performed using Stata version 13.0 (StataCorp. 2013.
Stata Statistical Software: Release 13. College Station,
TX: StataCorp LP).
Cost-per-episode of influenza-associated illness
The cost-per-episode of influenza-associated illness was
estimated as the sum of the facility-based medical costs,
household transportation costs, the costs of seeking
health care prior to the current visit, and the household
lost productivity cost (Additional file 1) [6, 13]. The rou-
tine service delivery cost at the facility – which included
buildings and equipment maintenance, transport, electri-
city, water, fuel, communication, stationery, and wages
for support staff – was estimated for each patient using
health facility administration data collected over the fi-
nancial year 2014 (Additional file 1). We also explored
the option of using the WHO-Choice estimates for rou-
tine healthcare service costs for hospitalized patients
(cost per bed day) and outpatients (cost per outpatient
visit) [14]. We found minimal differences compared to
when we used actual data and subsequently opted to re-
port costs calculated using the actual routine healthcare
service cost data collected from the study sites (Additional
file 1). Definitions and data sources of the cost compo-
nents are provided in Additional file 2.
National economic burden of influenza-associated illness
To estimate the annual economic burden of influenza-asso-
ciated illness, we used the published national annual
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incidence (between 2007 and 2013) of influenza-associated
hospitalizations and outpatient visits for children < 5 years
and persons ≥5 years [15]. We carried out a sensitivity ana-
lysis for the best- and worst-case scenario assuming a low
and high incidence of influenza-associated illness respect-
ively [15]. We applied the incidence rates to the population
size in 2014, projecting an annual growth rate of 2.7% from
the 2009 national census, to estimate the annual number of
hospitalizations and outpatient visits associated with influ-
enza illness [16, 17]. We used bootstrap samples – with
1000 replications of the same size as the original dataset
and sampled with replacement – to estimate the mean
costs which were then applied to the hospitalizations and
outpatient visits to estimate overall costs. All costs reported
in our analysis are in United States (U.S.) Dollars (1 US$ =
90 Kenya Shillings in 2014).
Ethical considerations
The KEMRI Ethical Review Committee (KEMRI
SSC-2492) and Institutional Review Board of U. S CDC
(CDC IRB # 6539) approved this study. Written in-
formed consent was obtained from all participants or
caretakers/guardians of all minors prior to enrolment in
the study and sample collection.
Results
Descriptive analyses
From July 2013 through August 2014, a total of 418 pa-
tients were initially recruited in the study. After excluding
patients who tested negative for influenza by rtRT-PCR
and those without follow up data, a total of 275
case-patients were included in the final analysis (Fig. 2
and Table 1). Among these were 105 inpatients (< 5 years
= 88; ≥5 years = 17), and 170 outpatients (< 5 years = 112;
≥5 years = 58). Among the inpatients, 90/105 (85.7%)
tested positive for influenza A only [influenza A(H1N1)
pdm09 = 43, A(H3N2) =30, not subtyped = 17], 13/105
(12.4%) were influenza B only cases, and 2/105 (1.9%)
tested positive for both influenza A and B. Of the outpa-
tients included in the analysis, 149/170 (87.6%) were influ-
enza A only cases [influenza A(H1N1) pdm09 = 67,
A(H3N2) =50, not subtyped = 32], 20/170 (11.8%)
were influenza B only cases, and 1/170 (0.6%) tested
positive for both influenza A and B.
The majority (73%) of the case-patients were children
< 5 years. Among persons ≥5 years, median age was 11
years (interquartile range [IQR], 7–30); only 7 (9%) were
aged ≥40 years. Overall 135 (49%) were males (Table 1).
The median length of hospitalization was 4 days (IQR,
3–6); 5 days (IQR, 3–7) among children < 5 years com-
pared to 4 days (IQR, 3–4) among older patients (p =
0.050). The average monthly household income was US$
225.83 (20,325 Kenya shillings).
Forty six percent of the case-patients aged < 5 years
were taken to care or had drugs bought for them over
the counter prior to enrollment compared to 20% for
persons aged ≥5 years (p < 0.001). The median (IQR)
number of workday opportunity losses was 2 days (0–6);
5 days (2–9) among inpatients vs. 1 day (0–3) among
outpatients (p < 0.001). The median (IQR) number of
school-days lost in the households of the case-patients
was 4 days (3–6); 3 days (1–6) among inpatients vs. 4
days (3–6) among outpatient (Table 1).
Cost of influenza-associated illness
We found differences in the distributions of the costs
per-episode of influenza by site among outpatients
(mean costs ranged from US$ 12.29–47.78; p = 0.002),
but no differences among inpatients (mean costs ranged
from US$ 110.82–130.97; p = 0.461).). We also found no
statistically significant difference when we compared
costs by influenza type [the median (IQR) was 91.34
(69.68–140.12) vs. 106.23 (39.57–170.05); p = 0.832) for
influenza A and B respectively among inpatients, and
10.45 (4.60–25.45) vs. 13.67 (6.00–18.56); p = 0.865) for
influenza A and B respectively among outpatients].
These comparisons excluded those who were co-infected.
Similarly, we did not find statistically significant differ-
ences in costs by the sub-types of influenza A positive
cases [the median (IQR) was 91.35 (68.13–141.30) for
A(H1N1) pdm09 vs. 108.16 (75.83 - 135.88) for A(H3N2);
p = 0.790 among inpatients, and 9.25 (4.18 - 22.34) for
A(H1N1) pdm09 vs. 12.71 (6.64 - 31.92) for A(H3N2);
p = 0.093 among outpatients].
The overall mean (SD) cost per episode among hospi-
talized patients was US$117.86 (88.04): < 5 years =
US$114.25 (90.03); and ≥ 5 years = US$137.45 (76.24)
(Table 2 and Additional file 2: Table S2). The mean (SD)
cost per episode among outpatients overall was US$19.82
(27.29): < 5 years = US$21.49 (31.42); and ≥ 5 years =
US$16.79 (17.30) (Table 3 and Additional file 2: Table S3).
The health facility service delivery mean (SD) costs among
inpatients were estimated at US$59.19 (59.39), and were
thirteen times higher compared to outpatients (US$4.34
[1.30]). Overall, the mean fraction of the total cost-per-e-
pisode of influenza-associated illness relative to the aver-
age monthly household income was 60% (95% CI 45–75)
among hospitalized patients. However, when the costs that
were paid by the government for children < 5 years were
excluded, cost-per-episode related to monthly income was
40% (95% CI 34–46). Cost-per-episode for outpatients
relative to monthly income was 12% (95% CI 10–14); 11%
(95% CI 9–13) if costs paid by the government for chil-
dren < 5 years were excluded.
Direct mean (SD) costs associated with influenza were
ten times higher for hospitalizations (US$ 75.43 [66.73])
compared to outpatient visits (US$ 7.68 [5.63]). The mean
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(SD) cost associated with hospitalization was US$75.42
(71.10) for children < 5 years and US$75.45 (36.27) for
persons ≥5 years (Table 2 and Additional file 2: Table S2).
For outpatient visits the mean (SD) cost was US$8.62
(6.15) for children < 5 years, and US$5.97 (4.07) for persons
≥5 years (Table 3 and Additional file 2: Table S3). The overall
mean (SD) indirect cost-per-episode of influenza-associated
illness was US$42.01 (41.54) (< 5 years =US$38.94 [38.59];
and≥ 5 years =US$58.61 [53.37]) among hospitalized patients
compared to US$12.84 (27.17) (< 5 years =US$13.87 [31.36];
and≥ 5 years =US$10.88 [16.65]) among outpatients.
National economic burden of influenza-associated illness
Assuming the lowest (< 5 years = 2.7 per 1000 children;
≥5 years = 0.2 per 1000 persons) and highest (< 5 years =
4.7 per 1000 children; ≥5 years = 0.4 per 1000 persons)
published incidence of hospitalizations associated with
influenza activity in Kenya [15], we estimated total hos-
pitalizations to range from 25,154 to 45,672 (< 5 years =
17,875 - 31,115; ≥5 years = 7279 - 14,557). These would
result in costs ranging from US$ 2.96 to 5.37 million
(< 5 years = US$2.04–3.55 million; ≥5 years = US$1.00–
1.99 million) (Table 4). Similarly, assuming lowest (< 5
years = 21.8 per 1000 children; ≥5 years = 4.3 per 1000 per-
sons) and highest rates (< 5 years = 58.0 per 1000 children;
≥5 years = 26.0 per 1000 persons) [15], we estimated that
outpatient visits associated with influenza would range
from 300,813 to 1,330,200 [< 5 years = 144,322 - 383,977;
≥5 years = 156,491 - 946,223]. These would translate to a
total cost ranging from US$5.96 to 26.35 million (< 5
years = US$3.09–8.23 million; ≥5 years = US$2.64–15.96
million). The overall cost associated with influenza (com-
bining in- and outpatients) could range from US$ 8.92 to
31.72 million.
Discussion
This is the first estimate of the economic impact associ-
ated with medically-attended influenza in Kenya. We
found that, depending on annual influenza virus circula-
tion, the costs associated with influenza in Kenya could be
as high as US$ 32 million. We estimated that the overall
mean cost per episode was US$118 for hospitalization and
US$20 for outpatient visits, a substantial burden for Kenyan
families when we consider their average monthly income,
the loss of self-employment wages by missed days at work,
and that most of medical costs are paid out-of-pocket.
Tested positive for influenza at the health facility by rapid diagnostic test 
(RDT) and were enrolled in the study (n=418) 
Hospitalized patients with 
initial interviews at the facility 
(n=178)
Patients with both initial and follow-up 
interviews done (n=156) 
Outpatients with initial 
interviews at the facility 
(n=240) 
With no follow-up data 
collected (n=22) 
Included in analysis (n=105) 
Tested negative for influenza 
by RT-PCR (n=51) 
Patients with both initial and follow-up 
interviews done (n=213) 
Included in analysis (n=170) 
With no follow-up data 
collected (n=27) 
Tested negative for influenza by 
RT-PCR (n=43)
Fig. 2 Data flow diagram
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Influenza vaccine is the most effective way to prevent
influenza and should be considered for groups at risk
of influenza-associated complications and hospitaliza-
tions in Kenya.
The overall cost-per-episode of influenza-associated
hospitalizations was six times higher when compared to
outpatient visits. This was driven by the facility-based
medical cost component, where the hospitalization cost
was thirteen-fold higher, and was similar to the results
published in Bangladesh [13]. Because of the higher fre-
quency of outpatient visits, the annual economic burden
for outpatient influenza-associated illness in Kenya was
substantially high relative to hospitalizations, which is
consistent with results reported from other studies [3, 13].
However, the overall cost-per-episode of influenza in our
study was lower than reported elsewhere in developed
countries [5, 18]. This could be explained by the relative
lower cost of healthcare and the comparatively low in-
come level in Kenya where the gross national income per
capita is estimated at US$939 [19].
The duration of hospitalization was higher for children
< 5 years compared to older persons. This is contrary to
findings reported elsewhere [6] and may be explained by
the fact that in our study population only 7 persons
were > 40 years old. Older adults tend to stay longer in
hospital due to complications associated with underlying
diseases [20]. We also found that the cost-per-episode
when the illness involved a child < 5 years old was similar
to the cost among older patients aged ≥5 years. Other than
the effect of underrepresentation of older patients in our
study, this finding could also be explained by the fact that
a higher percentage (46%) of children < 5 years compared
to older patients (20%) had sought healthcare or had drugs
bought over the counter prior to the hospitalization or
outpatient visit. The fact that an influenza-associated ill-
ness involving young children – who are at a high risk of
influenza-associated complications [21, 22] – also results
in high economic cost highlights the need for the develop-
ment of targeted vaccination and other preventive strat-
egies among this age group.
Table 1 General characteristics of study patients with influenza-associated illnesses in Kenya, July 2013–August 2014
Variable All data
(n = 275)
Inpatients Outpatients
< 5 years
(n = 88)
≥5 years
(n = 17)
Total
(n = 105)
< 5 years
(n = 112)
≥5 years
(n = 58)
Total
(n = 170)
Hospital, n(%)
Coast PGH 38 (13.8) 25 (28.4) 0 (0.0) 25 (23.8) 13 (11.6) 0 (0.0) 13 (7.7)
Nyeri PGH 35 (12.7) 28 (31.8) 5 (29.4) 33 (31.4) 2 (1.8) 0 (0.0) 2 (1.2)
Nakuru PGH 98 (35.6) 35 (39.8) 12 (70.6) 47 (44.8) 45 (40.2) 6 (10.3) 51 (30.0)
Tabitha Clinic (Kibera) 89 (32.4) 0 (0.0) 0 (0.0) 0 (0.0) 48 (42.9) 41 (70.7) 89 (52.4)
St. Elizabeth Hosp. (Lwak) 15 (5.5) 0 (0.0) 0 (0.0) 0 (0.0) 4 (3.6) 11 (19.0) 15 (8.8)
Sex of patient (Male), n(%) 135 (49.1) 50 (56.8) 7 (41.2) 57 (54.3) 58 (51.8) 20 (34.5) 78 (45.9)
Age of patient (< 5 years), n(%) 200 (72.7) 88 (100.0) N/A 88 (83.81) 112 (100.0) N/A 112 (65.9)
Relationship of respondent to patient, n(%)
Self 31 (11.3) 0 (0.0) 8 (47.1) 9 (8.6) 0 (0.0) 22 (37.9) 22 (12.9)
Mother 222 (80.7) 81 (92.0) 8 (47.1) 88 (83.8) 105 (93.8) 29 (50.0) 134 (78.8)
Father 13 (4.7) 4 (4.6) 0 (0.0) 4 (3.8) 6 (5.4) 3 (5.2) 9 (5.3)
Other 9 (3.3) 3 (3.4) 1 (5.9) 4 (3.8) 1 (0.9) 4 (6.9) 5 (2.9)
Sought care prior to this hospitalization/outpatient visit, n(%) 107 (38.9) 58 (65.9) 10 (58.8) 68 (64.8) 34 (30.4) 5 (8.6) 39 (22.9)
Purchased any medications prior to hospital/clinic visit, n(%) 77/107 (72.0) 42/58 (72.4) 7/10 (70.0) 49/68 (72.1) 24/34 (70.6) 4/5 (80.0) 28/39 (71.8)
Sought care after discharge from the hospital/clinic, n(%) 26 (9.5) 8 (9.1) 3 (17.7) 11 (10.5) 11 (9.8) 4 (6.9) 15 (8.8)
Household member(s) missed work due to illness, n(%) 177 (64.4) 72 (81.8) 17 (100.0) 89 (84.8) 54 (48.2) 34 (58.6) 88 (51.8)
Total number of workdays lost in a household, median(IQR) 4 (3–8) 7 (4–10) 6 (3–13) 6 (4–10) 3 (2–6) 3 (2–5) 3 (2–5)
Average number of household workdays lost due to illness,
median (IQR)a
4 (2–7) 5 (3–9) 6 (3–12) 5 (3–9) 3 (2–5) 3 (2–4) 3 (2–5)
Household member(s) missed school due to illness, n(%) 90 (32.7) 17 (19.3) 6 (35.3) 23 (21.9) 35 (31.3) 32 (55.2) 67 (39.4)
Total number of school days missed, median(IQR) 4 (3–6) 2 (1–6) 5 (4–9) 3 (1–6) 3 (2–6) 4 (3–7) 4 (3–6)
Paid for child care in the course of sickness, n(%) 6 (2.2) 3 (3.4) 0 (0.0) 3 (2.9) 1 (0.9) 2 (3.5) 3 (1.8)
Paid for child care in the course of sickness, n(%) 6 (2.2) 3 (3.4) 0 (0.0) 3 (2.9) 1 (0.9) 2 (3.5) 3 (1.8)
NA Not applicable; aCalculated as the total number of workdays lost by all household members who reported to be engaged in an income activity divided by the
number of persons who reported to be engaged in an income activity
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Influenza-associated illness also resulted in school
absenteeism among sick children, with a median of 4
days of missed school, which was comparable to find-
ings from a study conducted in Hong Kong [23], and
another study conducted in the US [4]. Notably, we
found that school absenteeism was higher among
households of outpatients compared to those of hos-
pitalized patients. A possible explanation could be
that older siblings may be asked to stay at home and
take care of the younger ones as the caretakers take
the sick child to a health facility. However, in a case
of hospitalization - where it may not be certain when
the mother/parent will return - young children may
be left at the care of relatives or neighbors.
Overall, a single episode of influenza-associated
hospitalization resulted in a substantial cost of approxi-
mately 60% of the household average monthly income
while outpatient-associated influenza costs represented
12%. Regardless of the fact that medical costs at the hos-
pital were covered by the government for children < 5
years [12], the overall resultant costs from an influenza-
associated hospitalization – which were paid out-of-
pocket (40% of the household average monthly income)
– could put a financial strain on families [24] and may
also negatively impact on other competing household
priorities such as food and education. Our data showed
that approximately 64% of household members lost days
at work which in many cases imply lost income as most
were self-employed. Considering the possibilities of
influenza-associated complications, the financial im-
pact to the household arising from such cases could
even be greater.
The mean cost-per-episode of influenza among chil-
dren < 5 years in our study (US$114) was similar to
the cost reported in a study of malaria patients that
was conducted in Kenya in 2009 which reported a
mean cost of US$100 [25]. However, there were some
differences in the methodologies of these studies that
would limit our ability to make direct comparisons.
Unlike in our study, death was included in the house-
hold indirect cost where it was calculated as the net
present value of future potential earnings. The result-
ant total indirect cost accounted for 60% of the over-
all mean cost per episode of malaria.
Our study had some important limitations. Our study,
incorporated data collected only from one year, and to
Table 2 Overall costs (US$d), including direct and indirect costs, related to influenza-associated illness among inpatients in Kenya,
July 2013–August 2014
Expenditure item < 5 years ≥5 years Total
n Mean (SD) Range (min-max) n Mean (SD) Range (min-max) n Mean (SD) Range (min-max)
Direct cost 76 75.42 (71.10) 6.45–573.17 14 75.45 (36.27) 23.89–143.91 90 75.43 (66.73) 6.45–573.17
Healthcare prior to hospital/
clinic visit
88 7.59 (16.95) 0.00–111.11 17 6.56 (8.48) 0.00–27.78 105 7.42 (15.86) 0.00–111.11
Total facility-based medical costs 83 59.81 (63.60) 6.45–561.50 15 55.77 (27.05) 14.67–117.90 98 59.19 (59.39) 6.45–561.50
Medications 83 13.90 (52.47) 0.33–480.23 15 18.31 (17.45) 0.33–64.78 98 14.58 (48.72) 0.33–480.23
Hospital bed fees 83 22.11 (13.95) 2.22–62.22 15 15.70 (6.13) 2.22–25.00 98 21.13 (13.24) 2.22–62.22
Procedure fees (non−/surgical) 83 2.48 (5.03) 0.00–41.11 15 2.44 (2.19) 0.00–5.56 98 2.48 (4.70) 0.00–41.11
Diagnostic tests 83 4.59 (9.72) 0.00–82.78 15 7.84 (10.33) 0.00–38.00 98 5.09 (9.83) 0.00–82.78
Routine health facility service
management costa
83 16.59 (10.24) 3.23–45.16 15 11.40 (4.02) 3.23–19.35 98 15.80 (9.72) 3.23–45.16
Total transportation costs 88 4.68 (8.02) 0.00–56.67 17 6.86 (9.78) 0.00–36.67 105 5.03 (8.32) 0.00–56.67
Personal car/taxi 10 10.88 (9.51) 0.56–32.22 5 23.91 (28.40) 0.67–66.67 15 15.22 (18.14) 0.56–66.67
Matatu/bus 70 9.39 (9.79) 0.89–67.78 17 6.74 (5.35) 0.67–17.89 87 8.87 (9.13) 0.67–67.78
Motorbike/bike/tuktuk 15 5.36 (5.08) 1.11–17.78 2 16.39 (12.18) 7.78–25.00 17 6.66 (6.73) 1.11–25.00
Healthcare after discharge 88 3.25 (5.95) 0.00–34.44 17 3.43 (7.53) 0.00–31.11 105 3.28 (6.19) 0.00–34.44
Child care cost 88 0.14 (0.81) 0.00–5.56 17 0.00 (0.00) 0.00–0.00 105 0.11 (0.75) 0.00–5.56
Indirect cost (Average household
productivity lossb)
81 38.94 (38.59) 0.00–187.50 15 58.61 (53.37) 11.11–180.56 96 42.01 (41.54) 0.00–187.50
Total cost per episodec 76 114.25 (90.03) 9.89–670.39 14 137.45 (76.24) 36.86–287.57 90 117.86 (88.04) 9.89–670.39
Total cost per episode paid out
of pocket
76 76.45 (55.13) 2.22–302.22 14 137.45 (76.24) 36.86–287.57 90 85.94 (62.49) 2.22–302.22
SD Standard Deviation, NA Not applicable; aRoutine healthcare facility management costs for healthcare service costs per day (equipment maintenance, electricity,
water, stationary, e.t.c); bEstimated by multiplying the average days when the household lost income opportunities by the household average daily income;
cSum of direct and indirect costs
d1 US$ = 90 Kenya Shillings
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account for potential variation on influenza circulation
from year to year, we used a sensitivity analysis based on
the range of previously estimated rates of influenza
hospitalization in Kenya. Moreover, due to the small
sample size, we were not able to breakdown costs associ-
ated with influenza by small age groups. The sample size
may also have affected our ability to find any differences
in influenza-associated costs by type and sub-type of
viruses; some studies have suggested differences in se-
verity of influenza-associated disease based on type and
subtype of virus which could lead to differences in costs
[26, 27]. Another potential limitation was that older pa-
tients were underrepresented in our patient-population
as healthcare seeking is low in this group [28], and our
cost estimates associated with influenza could be under-
estimated, principally considering the high prevalence of
underlying medical conditions among older patients that
could lead to prolonged hospitalization. Indeed, as rou-
tinely seen in our hospital-based surveillance, only 3% of
the study participants were aged ≥40 years and only 5%
of the study participants had been tested for HIV. Add-
itionally, data on other underlying comorbidities such as
asthma, diabetes, cardiac disease, and tuberculosis were
limited. With regard to the calculation of costs, we
estimated the facility-based medical-costs by applying
charges that were recorded on the hospital bill charge
sheets, the price catalogue charts, and the receipts
that were issued to the patients as a proxy for the ac-
tual cost. As such, the actual costs may have varied
by the extent to which these charges approximated
the true cost to the hospital. Moreover, we did not
include the physician’s fees in our analysis. We also
did not incorporate the indirect cost of days with re-
duced activity among case-patients, productivity loss
for non-income generating activities, and deaths in
our data collection and subsequently in the analysis.
This likely further served to underestimate the actual
costs associated with influenza. The self-reported
costs on prior expenditures and post-discharge expen-
ditures could have suffered some degree of under- or
over reporting as they were not substantiated by re-
ceipts. Lastly, we did not include costs incurred by
persons who did not seek care because of influenza
illness; costs of self-medication within the commu-
nity and related loss of productivity by these persons
went unmeasured.
Table 3 Overall costs (US$d), including direct and indirect costs, related to influenza-associated illness among outpatients in Kenya,
July 2013–August 2014
Expenditure item < 5 years ≥5 years Total
n Mean (SD) Range (min-max) n Mean (SD) Range (min-max) n Mean (SD) Range (min-max)
Direct cost 100 8.62 (6.15) 3.23–33.00 55 5.97 (4.07) 3.23–23.23 155 7.68 (5.63) 3.23–33.00
Healthcare prior to hospital/
clinic visit
110 2.04 (4.67) 0.00–27.78 58 0.17 (0.82) 0.00–5.56 168 1.39 (3.90) 0.00–27.78
Total facility-based medical costs 108 4.30 (1.27) 3.23–9.67 57 4.43 (1.36) 3.23–8.89 165 4.34 (1.30) 3.23–9.67
Medications 108 0.96 (1.11) 0.13–5.77 57 1.10 (1.20) 0.04–5.11 165 1.01 (1.14) 0.04–5.77
Hospital bed fees – NA NA – NA NA – NA NA
Procedure fees (non−/surgical) 108 0.00 (0.00) 0.00–0.00 57 0.00 (0.00) 0.00–0.00 165 0.00 (0.00) 0.00–0.00
Diagnostic tests 108 0.11 (0.51) 0.00–5.00 57 0.11 (0.24) 0.00–1.11 165 0.11 (0.43) 0.00–5.00
Routine health facility service
management costa
108 3.23 (0.00)e 3.23–3.23 57 3.23 (0.00)e 3.23–3.23 165 3.23 (0.00)e 3.23–3.23
Total transportation costs 112 0.48 (0.83) 0.00–4.44 58 0.25 (0.94) 0.00–5.11 170 0.40 (0.87) 0.00–5.11
Personal car/taxi 1 NE NE 0 NE NE 1 NE NE
Matatu/bus 42 3.91 (8.42) 0.44–41.67 6 8.24 (9.52) 0.22–23.33 48 4.45 (8.58) 0.22–41.67
Motorbike/bike/tuktuk 17 2.59 (1.95) 0.89–6.67 5 3.33 (1.96) 1.67–6.67 22 2.76 (1.93) 0.89–6.67
Healthcare after discharge 112 2.46 (4.77) 0.00–32.22 58 1.19 (3.48) 0.00–19.44 170 2.03 (4.40) 0.00–32.22
Child care cost 112 0.04 (0.42) 0.00–4.44 58 0.13 (0.78) 0.00–5.56 170 0.07 (0.57) 0.00–5.56
Indirect cost (Average household
productivity lossb)
106 13.87 (31.36) 0.00–222.22 56 10.88 (16.65) 0.00–69.44 162 12.84 (27.17) 0.00–222.22
Total cost per episodec 100 21.49 (31.42) 3.23–235.00 55 16.79 (17.30) 3.23–72.80 155 19.82 (27.29) 3.23–235.00
Total cost per episode paid out
of pocket
100 19.21 (30.70) 0.56–228.44 55 16.79 (17.30) 3.23–72.80 155 18.35 (26.69) 0.56–228.44
SD Standard Deviation, NA Not applicable, NE Not estimated; aRoutine healthcare facility management costs for healthcare service costs per day (equipment
maintenance, electricity, water, stationary, e.t.c); bEstimated by multiplying the average days when the household lost income opportunities by the household
average daily income; cSum of direct and indirect costs
d1 US$ = 90 Kenya Shillings; eNo variability as the same amount was used for all patients
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Conclusions
Our findings show that medically attended, influenza-asso-
ciated illness in Kenya generate substantial direct and indir-
ect costs. The burden is driven mostly by outpatient visits.
Whereas this study highlights an important societal eco-
nomic impact of influenza-associated illness, further studies
should explore the cost-effectiveness of targeted influenza
vaccination in Kenya and account for years lost due to
death or disability in order to guide vaccine recommenda-
tion policies.
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Table 4 Estimated annual costs (in millions of 2014 US$) of influenza-associated illnesses in Kenya
Cost Item (per episode) Hospitalized patients Outpatients
Best-case scenario Worst-case scenario Best-case scenario Worst-case scenario
Estimated
cases
Cost (US$d Millions)
(95% CIc)
Estimated
cases
Cost (US$d Millions)
(95% CIc)
Estimated
cases
Cost (US$d Millions)
(95% CIc)
Estimated
cases
Cost (US$d Millions)
(95% CIc)
Children < 5 yearsa 17,875 31,115 144,322 383,977
Total direct costs 1.34 (1.10–1.63) 2.34 (1.92–2.84) 1.25 (1.09–1.41) 3.33 (2.89–3.76)
Facility-based
medical costs
1.08 (0.89–1.34) 1.87 (1.54–2.33) 0.62 (0.59–0.66) 1.65 (1.56–1.75)
Transportation costs 0.08 (0.06–0.12) 0.15 (0.10–0.21) 0.07 (0.05–0.09) 0.18 (0.13–0.24)
Other costsb 0.20 (0.13–0.27) 0.34 (0.23–0.47) 0.66 (0.48–0.85) 1.76 (1.27–2.25)
Total indirect 0.70 (0.56–0.85) 1.21 (0.97–1.48) 2.01 (1.23–2.97) 5.35 (3.28–7.91)
Total costs 2.04 (1.73–2.41) 3.55 (3.01–4.19) 3.09 (2.32–4.07) 8.23 (6.18–10.84)
Persons ≥5 yearsa 7279 14,557 156,491 946,223
Total direct costs 0.55 (0.41–0.69) 1.10 (0.81–1.37) 0.93 (0.78–1.11) 5.64 (4.72–6.69)
Facility-based
medical costs
0.41 (0.32–0.53) 0.81 (0.63–1.07) 0.69 (0.64–0.75) 4.20 (3.89–4.55)
Transportation costs 0.05 (0.02–0.09) 0.10 (0.04–0.18) 0.04 (0.01–0.08) 0.24 (0.05–0.50)
Other costsb 0.07 (0.04–0.11) 0.15 (0.07–0.22) 0.23 (0.10–0.40) 1.42 (0.63–2.43)
Total indirect 0.43 (0.26–0.65) 0.86 (0.51–1.30) 1.69 (1.09–2.40) 10.24 (6.61–14.49)
Total costs 1.00 (0.71–1.30) 1.99 (1.42–2.59) 2.64 (1.99–3.38) 15.96 (12.02–20.43)
All ages 25,154 45,672 300,813 1,330,200
Total direct costs 1.89 (1.60–2.25) 3.44 (2.90–4.09) 2.32 (2.08–2.58) 10.24 (9.18–11.40)
Total indirect 1.06 (0.86–1.28) 1.92 (1.55–2.33) 3.87 (2.71–5.24) 17.11 (11.98–23.17)
Total costs 2.96 (2.57–3.41) 5.37 (4.66–6.19) 5.96 (4.80–7.49) 26.35 (21.22–33.14)
aEstimated using published rates of influenza-associated disease in Kenya [hospitalization rate (< 5 years = 2.7–4.7 per 1000; ≥5 years = 0.2–0.4 per 1000)
and outpatient rate (< 5 years = 13.0–58.0 per 1000; ≥5 years = 4.3–26.0 per 1000)]; bCombines costs for childcare, and healthcare seeking prior and after
hospitalization or outpatient visit; cMean cost and 95% confidence intervals estimated using 1000 bootstrap samples
d1 US$ = 90 Kenya Shillings (2014)
Best-case scenario: Assuming the lowest published incidence rate of influenza-associated illness
Worst-case scenario: Assuming the highest published incidence rate of influenza-associated illness
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